
Home » Ampio Pharmaceuticals to Test Investigational Pain Med as COVID-19 Treatment
Ampio Pharmaceuticals to Test Investigational Pain Med as COVID-19 Treatment

Ampio Pharmaceuticals said it will conduct a phase 1 clinical trial to test its investigational pain treatment Ampion (aspartyl-alanyl diketopiperazine) as a treatment for COVID-19 patients.
The company said it believes the nonsteroidal anti-inflammatory drug may help ease inflammation and improve patient outcomes.
Ampion is currently being developed for the treatment of pain due to osteoarthritis of the knee.
Upcoming Events
-
08Feb
-
09Feb
-
15Feb
-
16Feb
-
22Feb
-
07Mar